Postinflammatory pulmonary fibrosis

Summary

Postinflammatory pulmonary fibrosis (MONDO:0001438) is a disease with 11 GWAS associations across 5 studies. A subtype of pulmonary fibrosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• GWAS associations: 11

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	postinflammatory pulmonary fibrosis
Mondo ID	MONDO:0001438
DOID	DOID:12123
SNOMED CT	266368002
UMLS	C0175999
MedGen	511625
GARD	0022944
Is cancer (heuristic)	no

Data availability: 11 GWAS associations (5 studies).

Disease family

This is a subtype of pulmonary fibrosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › lower respiratory tract disorder › lung disorder › interstitial lung disease › pulmonary fibrosis › postinflammatory pulmonary fibrosis

Related subtypes (5): pulmonary fibrosis and/or bone marrow failure, telomere-related, diffuse pulmonary fibrosis, localized pulmonary fibrosis, tuberculous fibrosis of lung, graphite pneumoconiosis

Genetics & variants

GWAS landscape

11 GWAS associations across 5 studies. Top hits map to 4 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs35705950	1e-323	MUC5AC - MUC5B	G	0.87
rs2076295	1e-23	DSP	T	0.19
rs72709458	3e-14	TERT	C	0.19
rs2532254	1e-13	KANSL1	G	0.18
rs10069690	3e-12	TERT	C	0.14
rs55735727	1e-11	ACTRT3 - MYNN	A	0.14
rs3796145	2e-11	LRRC34	A	0.14

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90476032	Verma A	2024	5,815	438,251	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90478154	Verma A	2024	1,003	119,514	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480257	Verma A	2024	1,003	119,514	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90436230	Zhou W	2018	887	397,411	Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90476031	Verma A	2024	510	58,927	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	1
Tier 3: regulatory	0
Tier 4: intronic/intergenic	6

MAF distribution

Bucket	Variants
common (>=0.05)	7
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intron_variant	6
splice_region_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs35705950	11	1219991	G>A,T	0.089	splice_region_variant	MUC5AC - MUC5B	1e-323	Tier 2: splice/UTR
rs2076295	6	7562999	T>A,C,G	0.458	intron_variant	DSP	1e-23	Tier 4: intronic/intergenic
rs72709458	5	1283640	C>A,G,T	0.215	intron_variant	TERT	3e-14	Tier 4: intronic/intergenic
rs2532254	17	46178687	G>A	0.168	intron_variant	KANSL1	1e-13	Tier 4: intronic/intergenic
rs10069690	5	1279675	C>T	0.32	intron_variant	TERT	3e-12	Tier 4: intronic/intergenic
rs55735727	3	169770360	A>C,G,T	0.244	intron_variant	ACTRT3 - MYNN	1e-11	Tier 4: intronic/intergenic
rs3796145	3	169807074	A>C,G	0.242	intron_variant	LRRC34	2e-11	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.